Xolair 150 MG/1.2 ML powder VLS
Ended Awarded Last action
- Contract number
- SPE2DR26FDGH5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,213
Award facts
- Contract value 100% obligated
- $14,212.98 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $14,212.98 to DMS Pharmaceutical Group Inc. for Xolair 150 mg/1.2 ml powder vials on December 1, 2025, with an ultimate completion date of December 22, 2025. This firm fixed-price delivery order carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, serves as a critical supplier within the federal pharmaceutical supply chain, particularly for Department of Defense healthcare operations.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The parent IDC, awarded on November 13, 2025, carries a $499.999 billion ceiling value and extends through December 31, 2036, encompassing a 30-month base period with three 30-month option periods. The PPV-G GEN V program represents part of the broader $30.3 billion acquisition strategy designed to provide pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables, to support recurring medical supply needs of military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance on numerous delivery orders demonstrates its capability to fulfill the diverse and specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FDGH5?
SPE2DR26FDGH5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 1, 2025.
How much is contract SPE2DR26FDGH5 worth?
The government has obligated $14,213 on SPE2DR26FDGH5.
Is contract SPE2DR26FDGH5 an order under another contract?
Yes. SPE2DR26FDGH5 is a delivery order under SPE2DR25D9151, an indefinite delivery contract.
Was contract SPE2DR26FDGH5 competed?
The extent of competition for SPE2DR26FDGH5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award